Literature DB >> 26065653

Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.

Andrew Yee1, Austin N Oleskie1, Anne M Dosey1, Colin A Kretz1, Robert D Gildersleeve1, Somnath Dutta1, Min Su1, David Ginsburg2, Georgios Skiniotis3.   

Abstract

Binding to the von Willebrand factor (VWF) D'D3 domains protects factor VIII (FVIII) from rapid clearance. We performed single-particle electron microscopy (EM) analysis of negatively stained specimens to examine the architecture of D'D3 alone and in complex with FVIII. The D'D3 dimer ([D'D3]2) comprises 2 antiparallel D3 monomers with flexibly attached protrusions of D'. FVIII-VWF association is primarily established between the FVIII C1 domain and the VWF D' domain, whereas weaker interactions appear to be mediated between both FVIII C domains and the VWF D3 core. Modeling the FVIII structure into the three-dimensional EM reconstructions of [D'D3]2-FVIII ternary and quaternary complexes indicates conformational rearrangements of the FVIII C domains compared with their disposition in the unbound state. These results illustrate the cooperative plasticity between VWF and FVIII that coordinate their high-affinity interaction.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26065653      PMCID: PMC4543228          DOI: 10.1182/blood-2015-04-641696

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

2.  The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.

Authors:  E L Saenko; D Scandella
Journal:  J Biol Chem       Date:  1997-07-18       Impact factor: 5.157

3.  A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.

Authors:  P A Foster; C A Fulcher; T Marti; K Titani; T S Zimmerman
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

4.  Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.

Authors:  Lysiane Hilbert; Paquita Nurden; Claudine Caron; Alan T Nurden; Jenny Goudemand; Dominique Meyer; Edith Fressinaud; Claudine Mazurier
Journal:  Thromb Haemost       Date:  2006-09       Impact factor: 5.249

5.  Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure.

Authors:  M L Liu; B W Shen; S Nakaya; K P Pratt; K Fujikawa; E W Davie; B L Stoddard; A R Thompson
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

6.  The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.

Authors:  R J Wise; A J Dorner; M Krane; D D Pittman; R J Kaufman
Journal:  J Biol Chem       Date:  1991-11-15       Impact factor: 5.157

7.  Bioengineering of coagulation factor VIII for improved secretion.

Authors:  Hongzhi Z Miao; Nongnuch Sirachainan; Lisa Palmer; Phillip Kucab; Michael A Cunningham; Randal J Kaufman; Steven W Pipe
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

8.  Association of the factor VIII light chain with von Willebrand factor.

Authors:  P Lollar; D C Hill-Eubanks; C G Parker
Journal:  J Biol Chem       Date:  1988-07-25       Impact factor: 5.157

9.  Binding of factor VIII to von willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers.

Authors:  A V Bendetowicz; J A Morris; R J Wise; G E Gilbert; R J Kaufman
Journal:  Blood       Date:  1998-07-15       Impact factor: 22.113

10.  Solution structure of the major factor VIII binding region on von Willebrand factor.

Authors:  Nuha Shiltagh; John Kirkpatrick; Lisa D Cabrita; Tom A J McKinnon; Konstantinos Thalassinos; Edward G D Tuddenham; D Flemming Hansen
Journal:  Blood       Date:  2014-04-03       Impact factor: 22.113

View more
  16 in total

1.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

2.  FVIII-VWF dos-à-dos.

Authors:  Sriram Krishnaswamy
Journal:  Blood       Date:  2015-08-20       Impact factor: 22.113

Review 3.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

4.  The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.

Authors:  N C Leksa; P-L Chiu; G M Bou-Assaf; C Quan; Z Liu; A B Goodman; M G Chambers; S E Tsutakawa; M Hammel; R T Peters; T Walz; J D Kulman
Journal:  J Thromb Haemost       Date:  2017-05-03       Impact factor: 5.824

5.  The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis.

Authors:  Xianchi Dong; Nina C Leksa; Ekta Seth Chhabra; Joseph W Arndt; Qi Lu; Kevin E Knockenhauer; Robert T Peters; Timothy A Springer
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

6.  Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.

Authors:  Nadine Vollack-Hesse; Olga Oleshko; Sonja Werwitzke; Barbara Solecka-Witulska; Christoph Kannicht; Andreas Tiede
Journal:  Blood       Date:  2021-02-25       Impact factor: 22.113

7.  High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

Authors:  Glaivy Batsuli; Wei Deng; John F Healey; Ernest T Parker; W Hunter Baldwin; Courtney Cox; Brenda Nguyen; Joerg Kahle; Christoph Königs; Renhao Li; Pete Lollar; Shannon L Meeks
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

8.  The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.

Authors:  Ian W Smith; Anne E d'Aquino; Christopher W Coyle; Andrew Fedanov; Ernest T Parker; Gabriela Denning; Harold Trent Spencer; Pete Lollar; Christopher B Doering; Paul Clint Spiegel
Journal:  J Thromb Haemost       Date:  2019-09-08       Impact factor: 5.824

9.  Factor VIII binding affects the mechanical unraveling of the A2 domain of von Willebrand factor.

Authors:  Wenpeng Cao; Wenjing Cao; Wei Zhang; X Long Zheng; X Frank Zhang
Journal:  J Thromb Haemost       Date:  2020-07-23       Impact factor: 5.824

10.  Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.

Authors:  James R Fuller; Kevin E Knockenhauer; Nina C Leksa; Robert T Peters; Joseph D Batchelor
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.